Abstract
Amgen disclosed a series of 4-heteroaryloxy quinoline/quinazoline compounds as multiple kinase inhibitors, including hepatocyte growth factor (HGF) receptor tyrosine kinase c-Met and vascular endothelial growth factor (VEGF) receptor tyrosine kinase. These compounds are stated to have wide therapeutic applications for the treatment of a variety of cancers, hypertension, arteriosclerosis, myocardial infarction and rheumatoid arthritis.
Keywords::
- angiogenesis
- c-Met
- hepatocyte growth factor (HGF)
- hepatocyte growth factor receptor (HGFR)
- invasion
- kinase insert domain containing receptor (KDR)
- lymphocyte-specific protein tyrosine kinase (Lck)
- metastasis
- proliferation
- receptor tyrosine kinase (RTK)
- scatter factor (SF)
- vascular endothelial growth factor (VEGF) receptor
Patent Details
Title Compounds and methods of use
Assignee Amgen, Inc.
Inventors Harmange J, Booker S, Bauer D et al.
Priority date 23/01/2004
Filing date 24/01/2005
Publication date 11/08/2005
Publication no. WO2005073224